Skip to main content

Chronic Limb Threatening Ischemia

0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
2 programs
Esprit BTK™ Everolimus Eluting Resorbable Scaffold from AbbottN/A1 trial
Stealth 360™ Peripheral Orbital Atherectomy System from AbbottN/A1 trial
Active Trials
NCT07270575Not Yet Recruiting400Est. Dec 2032
NCT07270562Not Yet Recruiting250Est. Dec 2031
Reflow Medical
Reflow MedicalCA - San Clemente
1 program
Vessel recoil measurement 15 minutes post final treatmentN/A1 trial
Active Trials
NCT07465627Not Yet Recruiting40Est. Sep 2028

Trial Timeline

Clinical trial activity over time

2026
2027
2028
2029
2030
2031
AbbottStealth 360™ Peripheral Orbital Atherectomy System from Abbott
AbbottEsprit BTK™ Everolimus Eluting Resorbable Scaffold from Abbott
Reflow MedicalVessel recoil measurement 15 minutes post final treatment

Clinical Trials (3)

Total enrollment: 690 patients across 3 trials

NCT07270562AbbottStealth 360™ Peripheral Orbital Atherectomy System from Abbott

ORbital Atherectomy for Lesion Preparation in Patients With Chronic Limb-threatening ischEmia

Start: Apr 2026Est. completion: Dec 2031250 patients
N/ANot Yet Recruiting
NCT07270575AbbottEsprit BTK™ Everolimus Eluting Resorbable Scaffold from Abbott

REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia

Start: Apr 2026Est. completion: Dec 2032400 patients
N/ANot Yet Recruiting
NCT07465627Reflow MedicalVessel recoil measurement 15 minutes post final treatment

Vessel Recoil in Specific CLTI Populations

Start: Mar 2026Est. completion: Sep 202840 patients
N/ANot Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.